Diversified Trust Co. Has $6.82 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Diversified Trust Co. grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 25.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,336 shares of the biopharmaceutical company’s stock after buying an additional 25,285 shares during the period. Diversified Trust Co.’s holdings in Bristol Myers Squibb were worth $6,815,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of BMY. Gateway Investment Advisers LLC increased its holdings in shares of Bristol Myers Squibb by 10.0% during the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after purchasing an additional 10,284 shares during the period. CWA Asset Management Group LLC boosted its stake in shares of Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after buying an additional 30,909 shares during the period. Stephens Inc. AR increased its stake in Bristol Myers Squibb by 13.5% during the 3rd quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after acquiring an additional 32,476 shares during the period. Railway Pension Investments Ltd raised its holdings in Bristol Myers Squibb by 3.7% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after acquiring an additional 40,300 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $1,554,154,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $57.08 on Tuesday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The stock has a market capitalization of $116.25 billion, a P/E ratio of 16.55, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The stock has a fifty day moving average of $58.63 and a 200-day moving average of $51.94.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same period last year, the business earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. Bristol Myers Squibb’s payout ratio is 73.04%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Citigroup increased their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Leerink Partners increased their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price on the stock. Finally, Guggenheim reaffirmed a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $61.41.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. and EU approvals expanded Opdivo’s label to include classical Hodgkin lymphoma across adult and pediatric groups, broadening the immunotherapy’s addressable market and strengthening BMY’s oncology growth runway. FDA Approves BMY’s Opdivo Label Expansion in Classical Hodgkin Lymphoma
• Positive Sentiment: New Camzyos (mavacamten) data presented at ACC.26 reinforce BMY’s leadership in obstructive hypertrophic cardiomyopathy (oHCM), supporting commercial adoption and longer-term revenue growth for the cardiology franchise. Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos Data at ACC.26
• Positive Sentiment: BMY expanded its collaboration with AI-drug developer insitro, nominating new targets in an ALS program — a sign of continued R&D productivity and de‑risking via external partnerships. insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets
• Neutral Sentiment: Market commentary highlights BMY as an attractive high‑yield name for income investors, which can support demand for the stock in volatile markets but may limit upside if growth misses persist. Bristol-Myers Squibb: An Attractive High-Yield Stock Amid Market Uncertainty
• Neutral Sentiment: BMY’s CEO, Dr. Christopher S. Boerner, was appointed to Colgate‑Palmolive’s board — a reputational/leadership signal but not directly material to near‑term fundamentals. Colgate-Palmolive Taps Healthcare And Regional Marketing Expertise For Growth
• Negative Sentiment: Execution concerns remain after BMY’s February quarter missed EPS expectations (reported EPS below consensus) and FY‑2026 guidance that sits below some sell‑side forecasts — a near‑term headwind for the stock until growth from Opdivo/Camzyos and other programs is visible in results.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.